BRCA1/2-话题@MedSci

#BRCA1/2#

30篇内容 | 2316人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2190722, encodeId=ef812190e229a, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a> <a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a> <a href='/topic/show?id=2fab3683e8a' target=_blank style='color:#2F92EE;'>#卵巢切除术#</a>, objectTitle=JAMA Oncol：携带BRCA1和BRCA2序列变异的女性进行双侧卵巢切除术与全因死亡率, objectType=article, longId=815671, objectId=df538156e1e7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240302/1709363620934_5490734.png, objectUrl=/article/show_article.do?id=df538156e1e7, replyNumber=0, likeNumber=82, createdTime=2024-03-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=df538156e1e7, moduleTitle=JAMA Oncol：携带BRCA1和BRCA2序列变异的女性进行双侧卵巢切除术与全因死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df538156e1e7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190720, encodeId=37982190e2038, content=<a href='/topic/show?id=e6541220109' target=_blank style='color:#2F92EE;'>#MRI#</a> <a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=JAMA Oncol：携带BRCA1和BRCA2序列变异的女性进行MRI监测与乳腺癌死亡率, objectType=article, longId=815673, objectId=c0378156e303, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/102373157-95011716.1910x1000.jpg, objectUrl=/article/show_article.do?id=c0378156e303, replyNumber=0, likeNumber=93, createdTime=2024-03-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c0378156e303, moduleTitle=JAMA Oncol：携带BRCA1和BRCA2序列变异的女性进行MRI监测与乳腺癌死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0378156e303)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2094885, encodeId=268c2094885f6, content=在以往的认知里，<a href='/topic/show?id=c40399886f5' target=_blank style='color:#2F92EE;'>#靶向#</a>药、免疫治疗药是特定癌种、特定基因突变、特定靶点、特定通路才能用的药。不少患者基因检测结果没有理想的靶点，失去用药机会，或者尝试跨适应症用药，但跨适应症无法报销或申请赠药。现在，<a href='/topic/show?id=a0c31049e18d' target=_blank style='color:#2F92EE;'>#泛癌种#</a>广谱抗癌药（也称不限癌种的抗肿瘤类药物）的研发成功和上市，给了大家新希望！打破癌种限制让更多患者有药可用！这种不不好用癌种的治疗策略，也被称为“精准治疗”，主要源于<a href='/topic/show?id=5eae41e7007' target=_blank style='color:#2F92EE;'>#基因检测#</a>的结果。根据基因检测的结果，一旦发现对应的靶点，就可以使用某个对应的<a href='/topic/show?id=78aa999190f' target=_blank style='color:#2F92EE;'>#靶向治疗#</a>药物。靶点检测最初从乳腺癌和肺癌比较常见，目前逐步向所有的癌种扩展，包括<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>等。例如，<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a>患者要检测<a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a></a>、ROS1以及ALK，<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者要检测HER2，胃癌患者要检测HER2。但是，相比起数百种之多的癌症驱动基因，每一类癌症当中，能够被应用于治疗的基因突变还是太少了，远不能满足所有患者的需求。而且目前有靶点的药物的类别也仍然有限，<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>主要包括PD-1/PD-L1，<a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a></a>，<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>，RET，ALK，MET，BRAF V600E，<a href='/topic/show?id=f5d71312e50' target=_blank style='color:#2F92EE;'>#NTRK#</a>，<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>，<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>，MSI-H及dMMR，<a href='/topic/show?id=17a51049e230' target=_blank style='color:#2F92EE;'>#Claudin 18.2#</a>，FGFR, BCMA, GPC3, Mesothelin, <a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>; 血液肿瘤包括CD19, CD7等, objectTitle=梅斯盘点：10类23种不限癌种的抗肿瘤类药物, objectType=article, longId=744128, objectId=21a5e4412876, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221009/f3030c9f9187475299543971eaaf09a9.jpg, objectUrl=/article/show_article.do?id=21a5e4412876, replyNumber=0, likeNumber=265, createdTime=2022-10-20, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21a5e4412876, moduleTitle=梅斯盘点：10类23种不限癌种的抗肿瘤类药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21a5e4412876)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1518996, encodeId=f647151899611, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=83, createdTime=2022-04-12, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518995, encodeId=8de71518995bb, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险, objectType=article, longId=301442, objectId=1e71301442a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e71301442a7, replyNumber=0, likeNumber=163, createdTime=2022-03-24, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e71301442a7, moduleTitle=J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e71301442a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518994, encodeId=f76a151899457, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择, objectType=article, longId=300992, objectId=cea030099207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cea030099207, replyNumber=0, likeNumber=110, createdTime=2022-03-18, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cea030099207, moduleTitle=Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cea030099207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518993, encodeId=5221151899305, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, objectType=article, longId=295703, objectId=ea9c295e0337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9c295e0337, replyNumber=0, likeNumber=0, createdTime=2022-02-17, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9c295e0337, moduleTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea9c295e0337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518992, encodeId=e669151899207, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效, objectType=article, longId=295135, objectId=2c9b295135ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c9b295135ea, replyNumber=0, likeNumber=107, createdTime=2022-02-06, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c9b295135ea, moduleTitle=Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c9b295135ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518991, encodeId=c6cc1518991f3, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效, objectType=article, longId=221327, objectId=bdda22132edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdda22132edc, replyNumber=0, likeNumber=104, createdTime=2021-12-01, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdda22132edc, moduleTitle=Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdda22132edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518990, encodeId=3589151899063, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌的疗效, objectType=article, longId=218868, objectId=6faf2188681d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6faf2188681d, replyNumber=0, likeNumber=0, createdTime=2021-10-20, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6faf2188681d, moduleTitle=Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6faf2188681d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518989, encodeId=27fe15189893a, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=JAMA Oncol：BRCA1/2 基因突变携带者预防性输卵管切除术，术后生活质量仍然良好, objectType=article, longId=217455, objectId=556e21e455f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556e21e455f3, replyNumber=0, likeNumber=116, createdTime=2021-09-24, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556e21e455f3, moduleTitle=JAMA Oncol：BRCA1/2 基因突变携带者预防性输卵管切除术，术后生活质量仍然良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556e21e455f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518988, encodeId=f996151898898, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Clin Cancer Res：尼拉帕利治疗携带BRCA1/2胚系突变的晚期乳腺癌的疗效, objectType=article, longId=216770, objectId=e27f216e703d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e27f216e703d, replyNumber=0, likeNumber=98, createdTime=2021-09-08, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e27f216e703d, moduleTitle=Clin Cancer Res：尼拉帕利治疗携带BRCA1/2胚系突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e27f216e703d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518987, encodeId=fd90151898eb2, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Br J Cancer：CD4、CD8和 FOXP3阳性免疫细胞可作为BRCA1/2相关乳腺癌死亡率的预测标志物, objectType=article, longId=215568, objectId=10ce21556891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10ce21556891, replyNumber=0, likeNumber=114, createdTime=2021-08-12, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10ce21556891, moduleTitle=Br J Cancer：CD4、CD8和 FOXP3阳性免疫细胞可作为BRCA1/2相关乳腺癌死亡率的预测标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10ce21556891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518986, encodeId=7e14151898686, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌中的治疗活性, objectType=article, longId=214713, objectId=e63f214e13a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e63f214e13a8, replyNumber=0, likeNumber=100, createdTime=2021-07-25, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e63f214e13a8, moduleTitle=Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌中的治疗活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e63f214e13a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518985, encodeId=5716151898555, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=BRCA1/2突变的年轻患者是否适宜保乳手术？, objectType=article, longId=213883, objectId=856a2138838e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=856a2138838e, replyNumber=0, likeNumber=0, createdTime=2021-07-09, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=856a2138838e, moduleTitle=BRCA1/2突变的年轻患者是否适宜保乳手术？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=856a2138838e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518984, encodeId=c39515189840c, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌, objectType=article, longId=211199, objectId=ffa121119985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa121119985, replyNumber=0, likeNumber=113, createdTime=2021-05-14, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa121119985, moduleTitle=JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffa121119985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518983, encodeId=613a151898315, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , objectType=article, longId=209040, objectId=19e420904055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19e420904055, replyNumber=0, likeNumber=98, createdTime=2021-03-28, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19e420904055, moduleTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19e420904055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518982, encodeId=69051518982d8, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, objectType=article, longId=206058, objectId=87ad20605893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87ad20605893, replyNumber=0, likeNumber=105, createdTime=2021-01-24, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87ad20605893, moduleTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87ad20605893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518981, encodeId=bdb8151898147, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, objectType=article, longId=205690, objectId=826020569015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=826020569015, replyNumber=0, likeNumber=114, createdTime=2021-01-14, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=826020569015, moduleTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=826020569015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518980, encodeId=cf8b1518980c2, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, objectTitle=ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率, objectType=article, longId=205519, objectId=bf4a2055190b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf4a2055190b, replyNumber=0, likeNumber=95, createdTime=2021-01-10, rootId=0, userName=fangcong, userId=63ce11226326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf4a2055190b, moduleTitle=ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf4a2055190b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRCA1/2

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #卵巢癌# #BRCA1/2# #卵巢切除术#

JAMA Oncol：携带BRCA1和BRCA2序列变异的女性进行双侧卵巢切除术与全因死亡率

2024-03-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#MRI# #乳腺癌# #BRCA1/2#

JAMA Oncol：携带BRCA1和BRCA2序列变异的女性进行MRI监测与乳腺癌死亡率

2024-03-03发表于上海

lifestar (审核中...)

前往app查看评论内容

全文收起在以往的认知里，#靶向#药、免疫治疗药是特定癌种、特定基因突变、特定靶点、特定通路才能用的药。不少患者基因检测结果没有理想的靶点，失去用药机会，或者尝试跨适应症用药，但跨适应症无法报销或申请赠药。现在，#泛癌种#广谱抗癌药（也称不限癌种的抗肿瘤类药物）的研发成功和上市，给了大家新希望！打破癌种限制让更多患者有药可用！这种不不好用癌种的治疗策略，也被称为“精准治疗”，主要源于#基因检测#的结果。根据基因检测的结果，一旦发现对应的靶点，就可以使用某个对应的#靶向治疗#药物。靶点检测最初从乳腺癌和肺癌比较常见，目前逐步向所有的癌种扩展，包括#卵巢癌#，#胃癌#等。例如，#非小细胞肺癌#患者要检测 #EGFR#、ROS1以及ALK，#乳腺癌#患者要检测HER2，胃癌患者要检测HER2。但是，相比起数百种之多的癌症驱动基因，每一类癌症当中，能够被应用于治疗的基因突变还是太少了，远不能满足所有患者的需求。而且目前有靶点的药物的类别也仍然有限，#实体瘤#主要包括PD-1/PD-L1，#EGFR#，#ROS1#，RET，ALK，MET，BRAF V600E，#NTRK#，#BRCA1/2#，#KRAS#，MSI-H及dMMR，#Claudin 18.2#，FGFR, BCMA, GPC3, Mesothelin, #TP53#; 血液肿瘤包括CD19, CD7等

梅斯盘点：10类23种不限癌种的抗肿瘤类药物

2022-10-20

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2022-04-12

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险

2022-03-24

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择

2022-03-18

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效

2022-02-17

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效

2022-02-06

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效

2021-12-01

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌的疗效

2021-10-20

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

JAMA Oncol：BRCA1/2 基因突变携带者预防性输卵管切除术，术后生活质量仍然良好

2021-09-24

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Clin Cancer Res：尼拉帕利治疗携带BRCA1/2胚系突变的晚期乳腺癌的疗效

2021-09-08

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Br J Cancer：CD4、CD8和 FOXP3阳性免疫细胞可作为BRCA1/2相关乳腺癌死亡率的预测标志物

2021-08-12

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌中的治疗活性

2021-07-25

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

BRCA1/2突变的年轻患者是否适宜保乳手术？

2021-07-09

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌

2021-05-14

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果

2021-03-28

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS

2021-01-24

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响

2021-01-14

fangcong (审核中...)

前往app查看评论内容

#BRCA1/2#

ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率

2021-01-10

科室
- - 订阅+
  - 更多科室
工具
服务